Press Releases<< Back
CHF Solutions Webinar Highlighted Importance of Fluid Management in Patients Treated for COVID-19
Because COVID-19 patients are hemodynamically unstable, they need fluid replacement, which puts them at risk for developing volume overload, acute respiratory distress syndrome (ARDS), and other complications related to progressive congestion.
The medical panel unanimously agreed that fluid stewardship is very important in patients with COVID-19 who become critically ill, and that ultrafiltration is an option for efficient fluid removal and rapid decongestion, and a way to optimize the volume status of these patients in a predictable way.
The physicians described the many benefits that portable ultrafiltration devices, like CHF Systems’ Aquadex SmartFlow™, have over conventional renal replacement therapies, such as ease of use, and the speed with which therapy can be initiated in the ICU. They also cited the low extracorporeal volume (35 mL) for patients with hemodynamic instability, and the low blood flow rate, which is not achievable with conventional dialysis machines.
The webinar panel was moderated by Dr. Amir Kazory, M.D., FASN (
The learning objectives for the webinar were:
- Discuss the
World Health Organization(WHO) protocol, published March 13, 2020, and the importance of identifying volume overload in COVID-19-infected patients because the risk of volume overload is very high1
- Understand the risks associated with volume overload, importance of maintaining fluid balance, and benefits of using ultrafiltration in patients with volume overload
- Discuss training and personnel required to quickly implement access to ultrafiltration
- Listen to real-world critical care patient case studies
“We are pleased that the three physician panelists, who are experienced users of ultrafiltration technology in the critical care setting, were able to present a valuable solution for the treatment of critically ill COVID-19 patients,” said
An audio replay of the webcast, slides and a transcript are available at http://ir.chf-solutions.com/events.
About the Aquadex SmartFlow System
The Aquadex SmartFlow system delivers clinically proven therapy using a simple, flexible and smart method of removing excess fluid from patients suffering from hypervolemia (fluid overload). The Aquadex SmartFlow system is indicated for temporary (up to 8 hours) or extended (longer than 8 hours in patients who require hospitalization) use in adult and pediatric patients weighing 20 kg or more whose fluid overload is unresponsive to medical management, including diuretics. All treatments must be administered by a health care provider, within an outpatient or inpatient clinical setting, under physician prescription, both having received training in extracorporeal therapies.
Certain statements in this release may be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements about the clinical use of the Aquadex SmartFlow system in patients infected with COVID-19. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our ability to execute on our commercial strategy, the possibility that we may be unable to raise sufficient funds necessary for our anticipated operations, our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and other risks and uncertainties described in our filings with the
1 WHO reference number: WHO/nCoV/Clinical/2020.3
Claudia Napal DraytonChief Financial Officer, CHF Solutions, Inc.952-345-4205 email@example.com MEDIA: Brad PerrielloHealth+Commerce 617-817-1385 firstname.lastname@example.org
Source: CHF Solutions, Inc.